Federal grant delays, cancellations, and rescissions are curtailing HIV testing, surveillance, and community engagement, compounded by reduced CDC surveillance activity and an HIV workforce unable to ...
Guardant Health markets Shield, an FDA-approved blood test for primary colorectal cancer screening. The Harris Poll conducted the survey from Feb. 24-26, 2026, among 1,189 U.S. adults, ages 45 and ...
Postdischarge adverse drug event risk is amplified by frequent medication changes, formulary substitutions, and insurance coverage gaps, with wide variability in published incidence estimates and ...
L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms rather than used in isolation. Treatment interactions emerged: CLDN18.2-high ...
PREVENT risk estimation starts at age 30 and incorporates lifetime risk, enabling earlier identification of patients who warrant intensified lipid management and preventive therapies. LDL-C treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results